Generally, patients with isocitrate dehydrogenase 1 mutation and MGMT promoter methylation are more prone to PSP and have a better prognosis.[11] Pathological diagnosis is the gold standard for PSP of glioma. The gene discussed is MGMT; the disease is central nervous system cancer.